fluorobenzenes has been researched along with Right Ventricular Dysfunction in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, G; Ma, P; Pei, Y; Wang, X; Xu, Q; Yan, L; Zhang, W; Zhang, X; Zheng, P | 1 |
1 other study(ies) available for fluorobenzenes and Right Ventricular Dysfunction
| Article | Year |
|---|---|
Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Body Weight; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heart; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Nitric Oxide Synthase Type III; Organ Size; Protein-Arginine N-Methyltransferases; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Ventricular Dysfunction, Right | 2011 |